Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tipping the balance for the primary prevention of breast cancer.

Vogel VG.

J Natl Cancer Inst. 2010 Nov 17;102(22):1683-5. doi: 10.1093/jnci/djq435. Epub 2010 Nov 4. No abstract available.

PMID:
21051657
2.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S; PEARL Investigators..

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

PMID:
21051656
3.

Third-generation SERMs may face uphill battle.

Schmidt C.

J Natl Cancer Inst. 2010 Nov 17;102(22):1690-2. doi: 10.1093/jnci/djq477. Epub 2010 Nov 8. No abstract available.

PMID:
21060064
4.

Another selective estrogen-receptor modulator for osteoporosis.

Becker C.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847. No abstract available. Erratum in: N Engl J Med. 2010 Jul 22;363(4):398.

PMID:
20181977
5.

Lasofoxifene in postmenopausal women with osteoporosis.

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators..

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. Erratum in: N Engl J Med. 2011 Jan 20;364(3):290. Kucu kdeveci A [corrected to Kucukdeveci, A].

6.

Raloxifene therapy in the reduction of fractures.

Cefalu CA.

Am Fam Physician. 2000 Mar 1;61(5):1272, 1275, 1279-80. No abstract available.

7.

Lasofoxifene for postmenopausal women with osteoporosis.

Silva-Fernández L, Andreu JL.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9. No abstract available.

PMID:
20568310
8.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
9.

The rise of raloxifene and the fall of invasive breast cancer.

Jordan VC.

J Natl Cancer Inst. 2008 Jun 18;100(12):831-3. doi: 10.1093/jnci/djn177. Epub 2008 Jun 10. No abstract available.

PMID:
18544739
10.

The evolution of selective estrogen receptor modulators in osteoporosis therapy.

Hadji P.

Climacteric. 2012 Dec;15(6):513-23. doi: 10.3109/13697137.2012.688079. Epub 2012 Aug 1. Review.

11.

Not all selective estrogen response modulators are created equal: update on lasofoxifene.

Goldstein SR.

Int J Gynecol Cancer. 2006;16 Suppl 2:504. Review. No abstract available.

PMID:
17010058
12.

Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?

Sambrook P.

Best Pract Res Clin Rheumatol. 2005 Dec;19(6):975-81. Review.

PMID:
16301191
13.

Raloxifene examined for breast cancer prevention.

Young D.

Am J Health Syst Pharm. 2007 Sep 1;64(17):1774. No abstract available.

PMID:
17724350
14.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Maeda T, Ke HZ, Simmons H, Thompson D.

Clin Calcium. 2004 Oct;14(10):85-93. Review. Japanese.

PMID:
15577137
15.

[Evidence of raloxifene on postmenopausal osteoporosis].

Okano H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:374-80. Review. Japanese. No abstract available.

PMID:
18161135
16.
17.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
18.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

19.

The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.

Lufkin EG, Wong M, Deal C.

Rheum Dis Clin North Am. 2001 Feb;27(1):163-85, vii. Review.

PMID:
11285993
20.

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.

Osteoporos Int. 2003 Sep;14(9):741-9. Epub 2003 Jun 19.

PMID:
12827224

Supplemental Content

Support Center